Ipratropium bromide and Hyperparathyroidism secondary - a phase IV clinical study of FDA data

Summary:

Hyperparathyroidism secondary is reported as a side effect among people who take Ipratropium bromide (ipratropium bromide), especially for people who are female, 50-59 old, also take Nexium, and have Gastroesophageal reflux disease.

The phase IV clinical study analyzes which people have Hyperparathyroidism secondary when taking Ipratropium bromide. It is created by eHealthMe based on reports of 17,749 people who have side effects when taking Ipratropium bromide from the FDA, and is updated regularly.

What is Ipratropium bromide?

Ipratropium bromide has active ingredients of ipratropium bromide. It is often used in chronic obstructive pulmonary disease. eHealthMe is studying from 17,965 Ipratropium bromide users. Check the latest studies of Ipratropium bromide.

What is Hyperparathyroidism secondary?

Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary) is found to be associated with 698 drugs and 462 conditions by eHealthMe. Check the latest studies of Hyperparathyroidism secondary.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

17,749 people reported to have side effects when taking Ipratropium bromide.
Among them, 13 people (0.07%) have Hyperparathyroidism secondary.

Could Ipratropium bromide cause Hyperparathyroidism secondary?

Among these 13 people:

What is the gender of people who have Hyperparathyroidism secondary when taking Ipratropium bromide? *

female: 53.85 %
male: 46.15 %

What is the age of people who have Hyperparathyroidism secondary when taking Ipratropium bromide? *

What are other drugs people take besides Ipratropium bromide? *

What are other side effects people have besides Hyperparathyroidism secondary? *

Chronic Kidney Disease: 13 people, 100.00%
Acute Kidney Failure: 12 people, 92.31%
Nephrogenic Anaemia (anaemia due to kidney disease): 6 people, 46.15%
Nephropathy (damage to or disease of a kidney): 2 people, 15.38%
Death: 2 people, 15.38%
Renal Impairment (severely reduced kidney function): 1 person, 7.69%
Hypocalcaemia (levels of calcium in blood serum are abnormally low): 1 person, 7.69%
High Blood Pressure: 1 person, 7.69%
Anion Gap Abnormal: 1 person, 7.69%

What are the existing conditions these people have? *

Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 12 people, 92.31%
High Blood Pressure: 9 people, 69.23%
High Blood Cholesterol: 6 people, 46.15%
Blood Pressure Abnormal: 4 people, 30.77%
Infection: 4 people, 30.77%
Gout (uric acid crystals building up in the body): 4 people, 30.77%
Diabetes: 3 people, 23.08%
Cough: 3 people, 23.08%
Depression: 2 people, 15.38%
Hypersensitivity: 2 people, 15.38%

* Approximation only. Some reports may have incomplete information.

Do you take Ipratropium bromide and have Hyperparathyroidism secondary?

- Check whether Hyperparathyroidism secondary is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ipratropium bromide:

Ipratropium bromide (17,965 reports)

Browse all side effects of Ipratropium bromide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperparathyroidism secondary:

Hyperparathyroidism secondary (698 drugs)

Browse all the conditions that are associated with Hyperparathyroidism secondary:

Hyperparathyroidism secondary (462 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ipratropium bromide (the active ingredients of Ipratropium bromide) and Ipratropium bromide (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.